Adjusted for age, gender, insurance scheme, BMI, TC, LDL, HDL, triglyceride, haemoglobin, SBP/DBP, hypertension, dyslipidemia, presence of T2D complications (CVD, DR, or CKD) prior to the outcome of interest, medication use in terms of drug classes (biguanides, sulphonylurea, insulin, alpha- glucosidase inhibitors, DPP-4i, GLP1-RA, TZD, SGLT2i, meglitinides, statins) and the number of antihypertensive drugs. This evidence concerns the gene INS and chronic kidney disease.